In a report issued on May 5, Puneet Souda from SVB Securities maintained a Hold rating on Twist Bioscience (TWST – Research Report), with a price target of $40.00. The company’s shares closed last Friday at $31.39, close to its 52-week low of $28.21.
According to TipRanks.com, Souda ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.0% and a 33.6% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Guardant Health.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Twist Bioscience with a $43.83 average price target.
Based on Twist Bioscience’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $42.02 million and GAAP net loss of $45.56 million. In comparison, last year the company earned revenue of $28.16 million and had a GAAP net loss of $32.9 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The company also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. Twist Bioscience was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.
Read More on TWST: